Zydus launches Mirabegron ER Tablets in the US
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
The company will respond to the Warning Letter within the stipulated timelines
Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
These observations are procedural in nature and will be responded within the stipulated time
The observations are procedural in nature and will be responded to within the stipulated time
The Product is expected to be the first generic approval on the market
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Subscribe To Our Newsletter & Stay Updated